Fast Five Quiz: Genetics of Non–Small Cell Lung Cancer

Daniel S. Schwartz, MD, MBA


February 03, 2021

In contrast with EGFR mutations, KRAS mutations, which occur in about 1 out of 4 patients with NSCLC, are more common among patients with a history of smoking and less common among patients of Asian descent.

KRAS, EGFR, and ALK mutations are typically mutually exclusive, so EGFR and ALK mutations are not usually associated with KRAS positivity.

Of note, patients with KRAS-mutated NSCLC tend to have a poorer prognosis than patients without a KRAS mutation, and they are often resistant to TKIs targeting EGFR mutations. Experts suggest that other factors, such as PD-L1 status and the presence of other mutations, can help guide treatment decisions when a KRAS mutation is present.

Learn more about factors associated with KRAS mutation.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: